IntoCell and Xcellon Biologics to advance ADC development
Xcellon Biologics will incorporate IntoCell’s OHPAS drug-linker system into its range of ADC development suites.
Syngene Thematic ADC WP
Debiopharm and NetTargets to identify synergistic drug combos for ADCs
GSK targets Syndivia’s prostate cancer ADC in £268m buy
Takeda signs deal worth up to $11.4bn with Innovent for cancer drug hopefuls
Adcytherix gains $122m to propel ADC development
Tubulis closes $361m in Series C to advance cancer treatment
Turbine and AstraZeneca partner for ADC discovery
Synaffix and Qurient enter licensing deal for dual-payload ADC
